By Fineline Cube 
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) announced the enrollment of the first patient in the Phase III study of its oral pentavalent recombinant rotavirus attenuated live vaccine (Vero cells). This marks a significant step forward in the development of a vaccine designed to prevent rotavirus-induced gastroenteritis in infants.
Vaccine Profile
The vaccine targets the primary serotypes of rotavirus (G1, G2, G3, G4, and G9) responsible for gastroenteritis in China. It is formulated for infants aged 6 weeks to 32 weeks, offering protection against this common childhood disease.
Clinical Trial Progress
The initiation of the Phase III study underscores the vaccine’s potential to address a significant public health need. Rotavirus is a leading cause of severe gastroenteritis in infants and young children, and this vaccine aims to provide broad-spectrum protection through an oral administration route.
Market Potential
With its broad coverage of rotavirus serotypes, Kangtai’s vaccine is positioned to compete effectively in the growing market for pediatric vaccines. The company’s commitment to advancing this innovative solution highlights its dedication to improving child health outcomes.-Fineline Info & Tech